Bcl-2 inhibits calcineurin-mediated Fas ligand expression in antitumor drug-treated baby hamster kidney cells

Japanese Journal of Cancer Research

Volumn 91, Issue 7, 2000, Pages 706-714

  Simizu, Siro ^a   Shibasaki, Futoshi ^b   Osada, Hiroyuki ^a  

^a RIKEN   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Bcl 2; Calcineurin; Fas; Pironetin

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CALCINEURIN; CAMPTOTHECIN; CASPASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; PACLITAXEL; PIRONETIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL STRAIN BHK; CELL STRAIN HL 60; CELL TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARTIC ACID; CALCINEURIN; CASPASES; CELLS, CULTURED; CRICETINAE; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FAS LIGAND PROTEIN; FIBROBLASTS; HL-60 CELLS; HUMANS; KIDNEY; LUNG; MEMBRANE GLYCOPROTEINS; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRONES; TRANSFECTION; UP-REGULATION;

EID: 0033853385     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb01003.x     Document Type: Article

References (46)

1. Caspase-mediated activation of a 36-kDa myelin basic protein kinase during anticancer drug-induced apoptosis
2. Activation of MST/Krs and c-Jun N-terminal kinases by different signaling pathways during cytotrienin A-induced apoptosis
3. The fas death factor
4. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen
5. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
6. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
7. Prodomains-adaptors-oligomerization: The pursuit of caspase activation in apoptosis
8. Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells
9. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
10. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
11. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
12. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways
13. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
14. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction
15. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells
16. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
17. Bcl-2 functions in an antioxidant pathway to prevent apoptosis
18. Inhibition of Fas-induced apoptosis by Bcl-2
19. BCL-2 family: Regulators of cell death
20. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
21. Bcl-2 targets the protein kinase Raf-1 to mitochondria
22. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2
23. Molecular ordering of the cell death pathway. Bcl-2 and Bcl-x(L) function upstream of the CED-3-like apoptotic proteases
24. Bcl-2 expression prevents activation of the ICE protease cascade
25. 2+ fluxes
26. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
27. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis
28. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
29. Channel formation by antiapoptotic protein Bcl-2
30. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation
31. Cell cycle arrest and antitumor activity of pironetin and its derivatives
32. Apoptosis induction via microtubule disassembly by an antitumour compound, pironetin
33. Aspartate-based inhibitor of interleukin-1B-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells
34. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage
35. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines
36. P53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs
37. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
38. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells
39. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nucleur factors of activated T cell-dependent pathway
40. 2+-induced apoptosis through calcineurin dephosphorylation of BAD
41. Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas
42. Apoptosis induced by inhibitor of the plasma membrane NADH-oxidase involves Bcl-2 and calcineurin
43. Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)-mediated apoptosis in activation-induced T cell death involves calcineurin and protein kinase C, respectively
44. Cyclosporine induces cancer progression by a cell-autonomous mechanism
45. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells
46. Bcl-2-mediated drug resistance: Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription